GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes

In brief

The LIGHT-COG study is a 76-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. A total of 420 type 2 diabetes patients with early dementia are randomized 1:1 to either the active treatment group (receiving subcutaneous injections of mazdutide weekly, with stepwise dose escalation to a maintenance dose per protocol) or the placebo group (receiving matched placebo injections). The primary objective is to evaluate the potential disease-modifying effects of mazdutide on cognitive dysfunction in type 2 diabetes.

Key facts

Study ID

NCT07083154

Run by

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

People needed

420

Starts

2025-09-27

Expected to finish

2029-08-01

Last updated by the study team

2026-03-05

Who can join

Age: 50 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 2 diabetes mellitus (T2DM).
• Aged 50-75 years (inclusive), male or female.
• Early symptomatic dementia (Mild cognitive impairment or mild dementia), defined as:
• MMSE score >20 and <27,
• CDR global score 0.5-1.0 (inclusive), with a CDR memory subscore ≥0.5,
• Subjective memory complaints for ≥6 months.
• Stable glycemic control regimen for ≥3 months prior to screening, meeting one of the following:
• Lifestyle/dietary intervention alone (no glucose-lowering drugs),
• Oral antidiabetic drugs (OADs), with or without once-daily basal insulin.
• HbA1c 7.0-9.0% (inclusive) at screening.
• BMI ≥20 kg/m², with stable weight (fluctuation <5%) for ≥3 months.
• Stable treatment regimen for cognitive impairment for at least 3 months prior to screening and commit to its continuation throughout the study period, meeting one of the following criteria:
• No treatment: Not receiving any pharmacological or non-pharmacological interventions for cognitive impairment;
• Non-pharmacological therapy only: Engaged exclusively in non-drug interventions (e.g., cognitive training);
• Pharmacological therapy: Using approved symptomatic cognitive-enhancing medications (e.g., cholinesterase inhibitors, NMDA receptor antagonists), excluding disease-modifying therapies for Alzheimer's disease (AD).
• Ability to comply with systematic cognitive and functional assessments.
• Fully understands the trial protocol, voluntarily signs the informed consent form (ICF), and agrees to adhere to all study requirements and restrictions.

You may not qualify if…

• Evidence of other neurodegenerative diseases that may affect cognition, excluding Alzheimer's disease, including:
• Frontotemporal dementia (FTD) and its variants
• Parkinson's disease (PD), dementia with Lewy bodies (DLB)
• Progressive supranuclear palsy (PSP), corticobasal degeneration (CBD)
• Multiple system atrophy (MSA), multiple sclerosis (MS), Huntington's disease (HD), etc.
• Current diagnosis of a poorly controlled or unstable psychiatric disorder (including but not limited to schizophrenia, bipolar disorder, major depressive disorder, generalized anxiety disorder, personality disorders, etc.), which, in the investigator's judgment, may interfere with study assessments, affect treatment compliance, or increase participant risk.
• With a Patient Health Questionnaire-9 (PHQ-9) score ≥10 at screening, or a Generalized Anxiety Disorder Scale-7 (GAD-7) score ≥10 at screening.
• History of stroke (ischemic/hemorrhagic), transient ischemic attack (TIA), or epileptic seizure within 3 months prior to screening; Current or prior diagnosis of central nervous system (CNS) disorders that may impair cognitive function, including but not limited to:
• CNS infections, Intracranial tumors, Metabolic encephalopathy, Neurological disorders due to malnutrition, or Severe traumatic brain injury.
• Acute hyperglycemic/hypoglycemic events within 1 year, including: Diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), and Hypoglycemic coma
• Use of GLP-1R agonists, GLP-1R/GIPR dual agonists, or GLP-1R/GCGR dual agonists within 3 months prior to screening.
• Regular use (>2 doses/week) of moderate-to-strong anticholinergic drugs within 4 weeks prior to screening; Use within 3 months prior to screening of: Anti-Parkinsonian drugs, Antiepileptic drugs, Antipsychotics, Morphine and opioid analgesics (Exemption: Short-term use [<5 days] for surgery/acute injury, if completed >4 weeks before screening); Use within 4 weeks prior to screening of: CNS stimulants; Medical/recreational cannabis, cannabinoids, or cannabidiol (CBD).a. Moderate/high anticholinergics, antiparkinsonian/antiepileptic drugs.
• Alcohol abuse (defined as >21 units/week for men or >14 units/week for women; 1 unit = 360 mL beer, 150 mL wine, or 45 mL spirits).
• Medical history of:
• Medullary thyroid carcinoma (MTC), pancreatitis
• Multiple endocrine neoplasia type 2 (MEN2)
• Gallbladder/biliary disease, severe gastrointestinal disorders, or bowel resection
• Active malignancy
• Uncontrolled or potentially unstable diabetic retinopathy/maculopathy.
• Severe organ dysfunction, including:
• ALT/AST >3× upper limit of normal (ULN)
• eGFR <45 mL/min/1.73m² (CKD-EPI equation)
• Unstable angina, myocardial infarction (MI), or NYHA Class II+ heart failure within 3 months
• Known/suspected hypersensitivity to the investigational product or related compounds
• Pregnancy, lactation, or women of childbearing potential not using highly effective contraception.

Where it is running

• Department of Endocrinology, Huadong Hospital Affiliated to Fudan University — Shanghai, China (enrolling)
• Department of Endocrinology, Changzhou No.2 People's Hospital — Changzhou, Jiangsu, China (enrolling)
• Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University — Nanjing, Jiangsu, China (enrolling)
• Department of Endocrinology, Endocrine and Metabolic Disease Medical Center,Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University — Nanjing, Jiangsu, China (enrolling)
• Department of Endocrinology, Jiangsu Province Hospital of Traditional Chinese Medicine — Nanjing, Jiangsu, China (enrolling)
• Department of Endocrinology, Shanghai General Hospital — Shanghai, Shanghai Municipality, China (enrolling)
• Department of Endocrinology, Xiangya Hospital of Central South University — Changsha, Hunan, China
• The Second Affiliated Hospital of Dalian Medical University — Dalian, Liaoning, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.